TempoLife › Funkcijas › Health screening by age: which test and when › cervical-cancer

Cervical screening (HPV test)

Almost every country in the region has switched from looking for abnormal cells to looking for the virus that causes them. The test is better, so the gap between tests is longer — and in several countries you can now take the sample yourself.

Šī lapa apraksta skrīninga programmas; tā nav diagnoze, nav personīgs riska novērtējums un neaizstāj jūsu veselības aprūpes dienestu. Vecuma grupas nosaka katra valsts un tās mainās — saņemtais uzaicinājums un jūsu valsts lapā nosauktā iestāde ir svarīgāki par jebko, kas rakstīts šeit. Skrīnings ir domāts cilvēkiem bez simptomiem: jauns sabiezējums, redzamas asinis, mainījusies dzimumzīme, neizskaidrojams svara zudums vai pēkšņas redzes vai dzirdes pārmaiņas prasa ārsta apskati tūlīt, lai arī ko būtu rādījis nesenais skrīninga rezultāts.

Kur tas tiek organizēts un kādā vecumā

Katra šī reģiona valsts, kas to īsteno kā organizētu programmu, ar savu vecuma diapazonu. Diapazoni atšķiras tāpēc, ka nacionālās iestādes vienus un tos pašus pierādījumus izsver atšķirīgi, nevis tāpēc, ka kāda no tām kļūdītos.

The switch from cells to virus

Cervical screening used to mean cytology: a sample of cells scraped from the cervix, spread on a slide and examined for changes. It worked, and it drove cervical cancer down dramatically over decades, but it looks for damage that has already happened and a single sample misses a fair amount of it. Primary HPV testing looks instead for the high-risk human papillomavirus types that cause virtually all cervical cancer. The large European randomised trials, pooled by Ronco and colleagues, found HPV-based screening gave substantially better protection against invasive cervical cancer than cytology. Estonia, Norway, Sweden, Latvia and Denmark have all moved to it, and Finland uses it widely.

Why a longer interval is not less care

A negative HPV test is a much stronger reassurance than a negative smear, because it says the cause is absent rather than that the damage is not yet visible. That is why intervals lengthened when the test changed — five years is standard from 30, and Sweden lengthens it further in the older bands. People often read a longer gap as a cut. It is the opposite: the test is good enough that testing more often would mostly generate false alarms, because an HPV infection picked up at 28 will usually have cleared by itself by 30.

Taking the sample yourself

Self-sampling is the biggest practical change in this programme in a generation. A kit posted to your home, a swab you use yourself, a prepaid envelope back to the laboratory. Estonia offers it, and it exists in several forms elsewhere in the region. It exists because the women least likely to attend a speculum appointment are the women at highest risk, and a self-taken HPV sample performs well enough that reaching them matters more than the small difference in sample quality. A positive self-test is followed by a clinic examination; a negative one ends the round.

What a positive HPV result means

Mostly, it means you have a common infection. HPV is very common and the large majority of infections clear without doing anything at all. A positive result is triaged — usually by examining the same sample for cell changes — and depending on what that shows you are either re-tested in a year or referred for colposcopy, where the cervix is examined under magnification. Colposcopy is an outpatient appointment, not surgery. Cell changes that need treating are removed in a short procedure, and treating them is what prevents the cancer.

Vaccination does not replace it

HPV vaccination protects against the types responsible for most cervical cancer, and the vaccinated cohorts now reaching screening age have far less disease. It does not cover every high-risk type, and screening programmes across the region continue to invite vaccinated women. The likely future is fewer tests over a lifetime for vaccinated women rather than none, and the countries in this region will change their programmes at different speeds, as they did with HPV testing itself.

Avoti:Padomes 2022. gada 9. decembra Rekomendācija par vēža skrīningu (CELEX 32022H1213(01)) · Ronco and colleagues, pooled analysis of the four European HPV screening trials, The Lancet 2014 · Tervisekassa — cervical cancer screening and the home HPV kit · Cancer Registry of Norway — Livmorhalsprogrammet, HPV testing from 2023· pārbaudīts2026-09-07

Bieži uzdotie jautājumi

Pārējā vietnes daļa

Visi27skrīninga lapasJa rezultāts nav normas robežās